Phase I Dose Escalation Trial of Volasertib in Combination With Azacitidine in Patients With MDS or CMML
Status:
Terminated
Trial end date:
2016-12-16
Target enrollment:
Participant gender:
Summary
To investigate the maximum tolerated dose (MTD), safety, pharmacokinetics, and efficacy of
volasertib in combination with azacitidine in patients with myelodysplastic syndromes (MDS)
or chronic myelomonocytic leukemia (CMML) and not candidates for hematopoietic stem cell
transplant